Immunogen (IMGN) Misses Q1 EPS Views; Revenue Light of Consensus

October 28, 2016 7:15 AM EDT
Get Alerts IMGN Hot Sheet
Trade IMGN Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Immunogen (NASDAQ: IMGN) reported Q1 EPS of ($0.51), $0.13 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $7.66 million versus the consensus estimate of $21.12 million.

For earnings history and earnings-related data on Immunogen (IMGN) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment